Julphar is a public shareholding company based in Ras Al Khaimah (UAE). It was established in 1980 under the guidance of H H Sheikh Saqr Bin Mohammed Al Qasimi, the Ruler of Ras Al Khaimah, and is currently a leader in the production and distribution of pharmaceutical products.
Since inception, Julphar remains committed to meeting the needs of an evolving society and playing an instrumental role in global healthcare development. Its approach to a fast paced market is to focus on strategic initiatives, quality product development and ensuring responsible practices.
Julphar’s goal is to create high-quality products whilst maintaining a competitive cost. Julphar achieves this through a network of eleven world-class manufacturing plants, and a reliable logistics network which covers five continents.
Julphar contains a diverse portfolio of therapeutic products which targets a large range of major therapeutic segments including endocrinology, anti infective, cardiovascular and gastroenterology.
In 2012, Julphar has also become the only company in the Middle East to produce the raw material needed to make insulin, highlighting their commitment to diabetes management in the region.
Julphar is well positioned to meet tomorrow’s healthcare challenges.